Author:
Wang Hao,Yu Yang,Jiang Zheng,Cao Wen-Ming,Wang Zhenyu,Dou Jun,Zhao Yanling,Cui Yunfu,Zhang Hong
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Hortobagyi, G. N. Developments in chemotherapy of breast cancer. Cancer 88, 3073–3079 (2000).
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast cancer (Version 3.2015) (2015).
3. Tacar, O., Sriamornsak, P. & Dass, C. R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 65, 157–170 (2013).
4. Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R. & Cutts, S. M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 66, 4863–4871 (2006).
5. Pang, B. et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 4, 1908 (2013).
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献